US FDA approves new Gilead drug to market for HIV-1 infection

On February 8, Gilead Sciences announced that the US FDA approved the launch of its new drug, Biktarvy, as a daily monolithic tablet therapy for HIV-1 infection. Biktarvy consists of three components, bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg). Compared to Gilead's other anti-HIV drug, Descovy (FTC/TAF), Biktarvy has more bictegravir. This is a new unboosted integrase chain transfer inhibitor (INSTI). The efficacy and safety of this new drug was validated in four ongoing Phase 3 clinical trials.

Pet Test Kit

One-stop solution, one machine multi-test
The test time is 3 to 15 minutes, and the results are quickly released
Easy-to-use touch screen platform, multilingual operating system
Reagents are stored at room temperature for 24 months without cold chain transportation.

High sensitivity and specificity.

Maintenance-free.


Pet Test Kit,Dna acquisition test swab kit,It is used by veterinarians to quickly diagnose diseases in dogs and cats,High-precision pet colloidal gold detection kit

Jiangsu iiLO Biotechnology Co., Ltd. , https://www.sjiilobiotech.com